Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

Movement Disorders

Volumn 19, Issue 4, 2004, Pages 426-432

  Waters, Cheryl H ^a   Sethi, Kapil D ^b   Hauser, Robert A ^c   Molho, Eric ^d   Bertoni, John M ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d ALBANY MEDICAL CENTER   (United States)

^e CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Efficacy; MAO B inhibition; Motor fluctuations; Parkinson's disease; Safety; Zydis selegiline

Indexed keywords

LEVODOPA; PLACEBO; SELEGILINE;

ADULT; AGED; ARTHRITIS; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DYSKINESIA; DYSPEPSIA; FEMALE; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS OF COVARIANCE; MYASTHENIA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVA; SKIN CARCINOMA; THORAX PAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE; SELEGILINE; SEVERITY OF ILLNESS INDEX;

EID: 2342426425     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20036     Document Type: Article

References (36)

1. Colosimo C, De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999;6:1-21.
2. Quinn N. Drug treatment of Parkinson's disease. BMJ 1995;310: 575-579.
3. Hubble JP, Koller WC, Waters C. Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clin Neuropharmacol 1993;16:83-87.
4. Waters CH. Treatment of advanced stage patients with Parkinson's disease. Parkinsonism Relat Disord 2002;9:15-21.
5. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
6. Goldstein L. The "on-off" phenomena in Parkinson's disease - treatment and theoretical considerations. Mt Sinai J Med 1980;47: 80-84.
7. Cedarbaum JM, Silvestri M, Clark M, Harts J, Kutt H. L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease. Clin Neuropharmacol 1990;13:29-35.
8. Golbe Ll, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55.
9. Youdim MB. Biochemical characterization of the active site of brain monoamine oxidase. Monogr Neural Sci 1980;7:176-179.
10. Youdim MB, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect 1993;91:181-185.
11. Youdim MB, Brain monoamine oxidase (MAO) B: a unique neurotoxin and neurotransmitter producing enzyme. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:363-371.
12. Heinonen E, Anttila M, Lammintausta R. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994;56:742-749.
13. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997;33:91-102.
14. Mahmood I, Marinac JS, Willsie S, Mason WD. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharm Drug Dispos 1995;16:535-545.
15. Laine K, Anttila M, Huupponen R, Maki-Ikola O, Heinonen E. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 2000; 23:22-27.
16. Barrett JS, Rohatagi S, DeWitt KE, Morales RJ, DiSanto AR. The effect of dosing regimen and food on the bioavailability of the extensively metabolized, highly variable drug, Eldepryl (selegiline hydrochloride). Am J Ther 1996;3:298-313.
17. Waitzinger J, Ludwig G, Pabst G, Michaelis K, Reh C. Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). Int J Clin Pharmacol Ther 1996;34:427-432.
18. Shin HS. Metabolism of selegiline in humans. Drug Metab Dispos 1997:25:657-662.
19. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998;50:375-382.
20. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:228-234.
21. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2:791-795.
22. Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson disease: a double-blind study. N Y State J Med 1987;87:646-649.
23. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology 1989;39:1109-1111.
24. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Neurology 1988:11:45-55.
25. Kurihara K, Kita K, Hirayama K, Hara T. [Dysphagia in Parkinson's disease.] Rinsho Shinkeigaku 1993;33:150-154.
26. Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 1992;32:134-140.
27. Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson's disease. Dysphagia 1996;11:14-22.
28. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991;6:151-156.
29. Coates C, Bakheit AM. Dysphagia in Parkinson's disease. Eur Neurol 1997;38:49-52.
30. Fuh JL, Lee RC, Wang SJ, Lin CH, Wang PN, Chiang JH, Liu HC. Swallowing difficulty in Parkinson's disease. Clin Neurol Neurosurg 1997;99:106-112.
31. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor fluctuation in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071.
32. Lieberman A, Ranhosky A, Korts D, et al. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49:162-168.
33. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
34. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998;51:1057-1062.
35. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
36. Parkinson Study Group. A controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study). Ann Neurol 2003;54:27.